Background' Previous work demonstrated that 5-fluorouracil (5-FU) metabolism is a critical factor for treatment tolerability In order to study the predictivity of pharmacokinetics with respect to the occurrence of 5-FU toxicity, this study investigates the relationship between the pharmacokinetics of 5-FU and its metabolite 5-fluoro-5,6-dihydrouracil (5-FDHU), dihydropyrimidine dehydrogenase (DPD) activity in peripheral blood mononuclear cells (PBMNC) and treatment tolerability
Introduction
The response rate and therapeutic index of 5-FU have been improved by combination therapies, biochemical modulation and protracted infusion schedules; however, 5-FU treatment may be associated with a non-negligible risk of severe toxicity that could be life-threatening [1, 2] . The enzyme dihydropyrimidine dehydrogenase (DPD) catalyzes the rate-limiting step of 5-FU biotransformation to yield the first inactive metabolite 5-fluoro-5,6-dihydrouracil (5-FDHU) [3] . Although DPD is widely expressed in human tissues, the liver is the major source of this enzyme [4] , thus reflecting the pivotal role of hepatic catabohsm in 5-FU metabolic clearance. Previous studies suggested that the level of DPD activity in circulating lymphocytes reflects that of the liver [5, 6] , and DPD monitoring should be performed to prevent severe 5-FU-induced toxicities [1] . Indeed, abnormally low values of DPD activity were associated with the occurrence of major adverse effects after 5-FU treatment [7] , providing further evidence of a relationship between DPD activity of mononuclear cells of peripheral blood (PBMNC) and clearance of 5-FU [8] . However, a fatal toxicity by 5-FU has been described in a patient with normal DPD activity in PBMNC but markedly low activity in the liver [9] . In addition evidence has been provided of a weak correlation between DPD activity and 5-FU disposition, thus arguing against 5-FU dose individualization based solely on DPD analysis [10] . Although a number of studies have attempted to relate the impairment in DPD activity to the alterations of 5-FU disposition, no similar investigation was performed with respect to 5-FDHU, the DPD-dependent metabolic product of 5-FU, and nor were the abnormalities in 5-FU and 5-FDHU disposition examined with respect to treatment tolerability in a large population of patients. Therefore, the purpose of this work was to study the correlation between the pharmacokinetics of 5-FU/5-FDHU, and the activity of DPD in PBMNC, in order to select a predictive parameter of the occurrence of severe gastrointestinal toxicities in patients given adjuvant 5-FU for colorectal cancer.
Patients and methods

Patients and treatment
One hundred ten chemotherapy-naive patients with histologically confirmed, surgically resected colorectal adenocarcinoma of Dukes' C stage, were consecutively enrolled in this study The group was composed of 62 men (median age, 60 years, range 36 to 79) and 48 women (median age, 61 years, range 39 to 76) Eligibility criteria included 1) one month of time interval between surgery and the start of chemotherapy, 2) an Eastern Cooperative Oncology Group (ECOG) performance status <2, and 3) normal values of bone marrow, hepatic and renal functions Patients were given adjuvant chemotherapy with 5-FU 370 mg/m 2 /day i v bolus plus leucovonn 100 mg/m 2 /day for five consecutive days, every four weeks Chemotherapy-induced toxicities were assessed by physician examination, EKG, unnalysis. serum biochemistry and blood cell count with differential prior to the start of the next cycle of chemotherapy, or earlier if indicated by clinical signs or symptoms of toxicity, and scored according to the World Health Organization (WHO) criteria The study was approved by the Ethics Committee of Pisa University Hospital, and investigations on DPD activity and pharmacokinetics of 5-FU/5-FDHU were performed after obtaining written informed consent from patients
Materials
All chemicals were obtained from Sigma Chemical Co (St Louis, Missouri) and were of analytical grade Lymphoprep Separation Medium was purchased from 1CN (Irvine, California), 5-FU and 5-FDHU for calibration standards and enzyme activity study were kindly provided by Hoffmann-La Roche (Basel, Switzerland), and reconstituted at 1 mg/ml in KH 2 PO 4 35 mM (pH 74) immediately before use
Collection of PBMNC and assay of DPD activity
In all patients, 15 ml of blood were drawn before 5-FU dosing on day 1 of the first cycle between 900 A M and 10 00 AM from a catheter placed in a peripheral vein of the forearm, kept in hepannized tubes and diluted 1 I with phosphate-buffered saline (PBS, pH 7 4) Blood was layered over Lymphoprep Separation Medium and centnfuged for 40 min at 1100 rpm After centrifugation the PBMNC layer was removed and washed twice with PBS, subsequently contaminating erythrocytes were lysed by diluting the cell suspension 1 8 (v/v) with an hypotonic solution (KHCO, 10 mM, NH 4 C1 160 mM, EDTA 0 13 mM) for 15 min at room temperature Cell suspension was then centnfuged at 10000 rpm for 15 min and the resulting pellet was washed with PBS and finally resuspended in 35 mM sodium phosphate buffer (pH 7 4) Cells were freeze-thawed three times in liquid nitrogen and centnfuged at 15000 rpm for 25 min at 4°C The supernatant was collected and protein concentration in crude cytoplasmic extracts was measured by the Protein Assay Kit (Sigma) The cytosolic extracts from PBMNC were then immediately assayed for DPD activity as previously described [II] though with minor modifications Briefly, 0 1-0 3 mg of cytosolic proteins, 5-FU (20 uM), reduced (3-nicotinamide-adenine dinucleotide phosphate (250 uM), P-mercaptoethanol (2 mM) and MgCl 2 (2 5 mM), were combined in a reaction volume of 0 5 ml with 35 mM sodium phosphate buffer, pH 74, and incubated for 30 min at 37 °C The reaction was stopped by adding the solvents for 5-FU and 5-FDHU extraction and their levels were determined according to the procedure described in the section 'Assay of 5-FU and 5-FDHU levels in cylosolic and plasma samples' Moreover, in five patients who experienced severe toxicity, DPD activity was reevaluated following the same procedure, when they fully recovered from the adverse drug reaction
Plasma sampling
The disposition of 5-FU and its catabolite 5-FDHU was evaluated in patients on day 1 of the first cycle of therapy Blood samples (4 ml each) were drawn between 900 A M and I 00 PM from a catheter placed in a peripheral vein of the forearm before (baseline) and 5, 15, 30, 45, 60, 90 min and three hours after 5-FU 1 v bolus and collected in hepannized tubes Samples were centnfuged within 10 min after their collection and plasma was frozen at -20 °C for later analysis of 5-FU and 5-FDHU concentrations In preliminary experiments, designed to assess the stability of 5-FU and 5-FDH U in whole blood, the degradation of drug and metabolite was negligible over three hours at 4 °C since the HPLC analysis of blood samples, added with exogenous compounds at concentrations ranging from 0 08 to 75 ug/ml, revealed a < 5% loss of 5-FU or 5-FDHU Assay of 5-FU and 5-FDHU levels in cytosolic and plasma samples Plasma and PBMNC samples (0 5 ml each) were added with 25 ul of sodium acetate I M, pH 4 8, 250 ul of sodium sulfate 0 2 g/ml, 5-fluorocytosine as internal standard (10 ug/ml) and 7 ml of diethyl ether/rt-propanol (84 16, v/v) Samples were shaken in a rotator for 15 min, then centnfuged at 3500 rpm for 10 min and 6 ml of supernatants were transferred in tubes and evaporated in a thermostated bath (45 °C) under N 2 flow Organic extracts were reconstituted with 250 ul of KH 2 PO 4 50 mM (pH 4 0), vortexed and sonicated for 0 5 min After centrifugation for 15 min at 15000 rpm, clear supernatants were transferred to autosampler vials and eluted through Hypersil BDS C|g stationary phase (250 x 4 6 mm, 5 urn, Alltech, Deerfield, Illinois) with KH2PO4 50 mM, pH 4 0, at flow rate of 1 ml/min Eluents were monitored at 200 nm and analyzed by the Millennium 2 1 software (Waters, Milford, Massachusetts) Standard calibration curves were obtained by adding 5-FU and 5-FDHU to 0 5 ml of blank plasma or PBMNC cytosolic extracts obtained from healthy donors on each day of analysis, resulting in final concentrations that ranged from 008 to 75 ug/ml The range of linearity of the HPLC method was from 0 08 ng/ml to 75 ug/ml, and the assay was characterized by a within-day coefficient of vanation (CV) from -1 5% to 6 6% and from -1% to 5 2% for 5-FU and 5-FDHU, respectively, whilst the between-day CV for both 5-FU and 5-FDHU ranged from 2 0% to 9 5%, in a four-day assay. The recoveries of 5-FU and 5-FDHU were 82% and 79%, respectively
Pharmacokinetic analysis
Plasma levels of 5-FU and 5-FDHU from each patient were fit according to a two-compartment open model, using non-linear leastsquares regression analysis by means of a computer software (APO2PR, MediWare, Groningen, The Netherlands) Distnbution and terminal half-lives (t|/2<x and ti/2p\ respectively), area under the plasma concentration vs time curve (AUC), total-body clearance (CL), and apparent volume of distribution (Vd) were calculated Peak plasma concentrations (Cma,) and time to reach it (T ma *) for 5-FU and 5-FDHU were determined from visual inspection of plasma concentration vs time curves
Analysis of data
Values are expressed as mean ± standard error (SE). The correlations between DPD activity, pharmacokinetic parameters of 5-FU/5-FDHU and chemotherapy-induced toxicities were assessed by linear regression analysis All cycles were divided in two groups, none or mild toxicity (non-toxic group, WHO grade < 1) and moderate-to-severe adverse effects (toxic group, WHO grade >2), on the basis of the gastrointestinal toxicity recorded after the first cycle of chemotherapy [11] One-way analysis of vanance (ANOVA) followed by the StudentNewmann-Keuls test was used to evaluate the differences in pharmacokinetic parameters and DPD activity among toxicity-related subgroups, while the x 2 test was used to assess the risk of toxicity on the basis of threshold values of pharmacokinetic parameters and DPD activity The a priori level of significance was set at P < 0 05
Results
Plasma disposition of 5-FU and 5-FDHU
The plasma disposition of 5-FU in 110 patients revealed a biphasic elimination, with a distribution phase characterized by a rapid decrease in drug levels, followed by a slow elimination phase. The AUC was 9.25 ± 0.63 hx ug/ml, and the C max (37.20 ± 4.03 ug/ml) was detected at the first sampling time ( 
DPD activity in PBMNC
The mean value of DPD, as measured in cytosolic extracts of PBMNC of 110 patients, was 197.22 ± 11 34 of 5-FDHU produced/min/mg of protein (95% confidence interval (95% CI): 174.75-219.69 pmol 5-FDHU/ min/mg protein). Moreover, the mean DPD activity in female patients (193.45 ± 15.80 pmol/min/mg protein) was 3 4% lower than in males (200.17 ± 16.1 pmol/min/ mg protein); however, the difference was not significant.
Treatment-induced toxicities
After completing the first cycle of therapy, gastrointestinal toxicities were evaluated according to WHO criteria.
In 84 patients the administration of 5-FU was associated with mild toxicity, including nausea or vomiting, diarrhea or mucositis of WHO grade 0-1. On the contrary, the treatment induced moderate-to-severe mucositis and diarrhea (WHO grade ^2) in 26 subjects, who required supportive care and pharmacological treatment of diarrhea or vomiting. The daily administered dose of 5-FU was reduced in 15 patients, or the treatment was discontinued in three patients. Five out of twenty-six patients experienced the worse toxicity, with diarrhea and /or stomatitis WHO grade 3-4, associated with mild-tomoderate nausea /vomiting, and in one case, handfoot syndrome ( Table 1) ; three of them required hospitalisation due to the severity of toxicity. Febrile neutropenia, defined as absolute neutrophil count <5 x 10 9 cells/1 with fever ^ 38.5 °C (single measurement) or > 38.0 °C in two measurements separated by 12-hour period, was observed in three out of five patients who experienced the worst g.i. toxicity (Table 1) . On the contrary, in other patients the changes in blood counts were not clinically significant and were not the reason of delay, interruption or dose-reduction of chemotherapy.
Relationships between toxicity, DPD activity and pharmacokinetics
The mean levels of 5-FU in patients with grade $s2 gastrointestinal toxicity were higher than patients with grade ^ 1 toxicity at any sampling time (Figure 1 ). Marked abnormalities in pharmacokinetic parameters were observed in five patients who experienced the worse toxicity (grade 3-4 diarrhea or stomatitis lasting for five to eight days; Table 1 ). These patients displayed significant changes in the AUC and CL values as compared to the general population, suggesting enhanced exposure and impaired systemic elimination of 5-FU ( Table 1) .
The AUC value of 5-FDHU was decreased in patients with grade >2 vs. J% 1 toxicity (10.51 ± 1.02 vs 12.91 ± 0.85 hx ug/ml) and was further reduced in Figure 2 Correlation between chemotherapy-induced gastrointestinal (GI) toxicity and pharmacokinetic parameters of 5-FU, including AUC, CL, C,., and Vd. GI toxicity WHO grade > 2 and < 1. n = 26 and n = 84 patients, respectively patients with grade >3 toxicity (8 98 ± 1.02 hxug/ml), the differences being not significant (Table 1) . However, the DPD activity was abnormally low in only two of them, while in the remaining three subjects the enzyme activity was superior to the limit of 100 pmol 5-FDHU/ min/mg protein ( Table 1 ). The DPD activity was reevaluated in these five patients after recovery from toxicity, but no differences were noted when compared to baseline (before 5-FU treatment). Moreover, not all patients with low PBMNC DPD activity experienced moderate or severe toxicity, because 16 out of 84 patients who tolerated the treatment well (g.i. toxicity WHO gradê 1) had an enzyme activity between 70 and 100 pmol/ min/mg of protein.
Significant relationships were observed between the degree of toxicity and pharmacokinetic parameters of 5-FU, including AUC, CL, Vd and C mux (Figure 2 ). In particular, the decrease in 5-FU CL (grade #s2 vs ^1 toxicity, 56.30 ± 3.60 vs. 35 28 ± 3.31 1/h/m 2 , respectively, P < 0 005) and the increase in AUC (grade ^2 vs. sgl toxicity, 13.59 ±2.05 vs. 7.91 ±0 44hxug/ml,/ > < 0 001) and C max (grade ^ 2 vs. sj 1 toxicity, 55 97 ± 12.51 vs. 31.48 ± 3 45 ug/ml, P < 0.01) were related to gastrointestinal toxic effects (Figure 2 ), thus reflecting an enhanced systemic exposure in patients who then suffered from severe toxicity. The C max of 5-FU in patients who experienced WHO grade 3-4 toxicity was lower than in the general population, and this discrepancy could be dependent on an undetected earlier plasma peak of 5-FU, while the higher 5-FU AUC values could be due to a slower catabolism of 5-FU as evidenced by the longer terminal half-lives with respect to the general population (mean ± SE, 0.52 ± 0.15 vs. 0.36 ± 0.05 h, respectively). Even though the decrease in 5-FDHU AUC was not significantly related to the severity of adverse events (12.91 ± 0.85 vs 10 51 ± 1.02 hxug/ml, in patients with < 1 vs. ^2 toxicity, respectively), the comparison of the pharmacokinetic parameters with the severity of toxicity induced by chemotherapy revealed that the 5-FU/5-FDHU AUC ratio displayed the higher correlation ( Figure 3 ) In particular, a threshold limit of 0.9 for 5-FU/5-FDHU AUC ratio (* 2 test, P < 0.0001) and of 42 1/h/m 2 for 5-FU CL (x 2 test, P < 0.05) was predictive of toxicity, both values being the lower and upper limits of the 95% CI, respectively, in patients who suffered from WHO grade ^ 2 toxicities (Figure 3) The mean value of DPD activity in patients with grade > 2 toxicity was lower than that of subjects with grade ^ 1 (170.31 ± 16.59 vs. 205.65 ± 13.87 pmol/min/ mg, respectively), but the difference was not statistically significant ( Figure 3) . Moreover, no correlations were found between values of DPD activity vs. the AUC and CL of 5-FU or AUC of 5-FDHU of individual patients, and it was not possible to identify a significant threshold limit for DPD activity in PBMNC.
Discussion
This work investigated 5-FU and 5-FDHU pharmacokinetics, DPD activity, and gastrointestinal toxicity in an attempt to establish a correlation between drug distribution and toxicity in colorectal cancer patients who were given adjuvant therapy. In five patients who experienced severe gastrointestinal toxicities (grade 3-4 diarrhea or stomatitis), marked changes in 5-FU pharmacokinetic parameters, particularly AUC and CL, and decrease in 5-FDHU AUC were observed with respect to subjects who tolerated the treatment well. These observations suggest that the reduction of systemic elimination of 5-FU is responsible for the occurrence of severe toxicity [1, 10, 12] . However, only in three out of five patients who suffered from a grade ^ 3 gastrointestinal toxicity, the DPD activity in PBMNC was lower than 100 pmol/min/mg protein, while in the remaining subjects DPD was moderately decreased or normal, based on the threshold values of 100 or 150 pmol/min/ mg protein previously reported [11, 13, 14] When the pharmacokinetic parameters of patients who reported moderate-to-severe g.i. toxicities (WHO ^ 2) were compared with those who experienced grade ^ 1 toxicity, the decrease in CL and the increase in AUC values of 5-FU were significant, while the 5-FDHU AUC was not. These differences suggest that gastrointestinal toxicity is mainly related to changes in drug exposure and elimination. Although mean differences in 5-FDHU AUC were not significant between groups, the ratio between the AUC values of the substrate 5-FU and the metabolic product 5-FDHU was related to the severity of toxicity better than any other pharmacokinetic parameter, and the threshold limit of 0.9 for the AUC ratio is predictive for the risk of gastrointestinal toxicity. This observation is in agreement with that reported by Gamehn et al. [15] , who found a significant correlation between plasma dihydrouracil/uracil ratio and 5-FU-induced toxicities. However, low and/or variable endogenous uracil plasma levels and differences in DPD affinity for 5-FU or uracil [16] may adversely affect the reliability of the evaluation of the relationship between uracil/dihydrouracil ratio and treatment-induced toxicities.
The present DPD activity, as measured in PBMNC, showed mean and median values similar to those previously reported in French (mean and median, 222 and 211 pmol/min/mg, respectively) [5] and white American populations (mean ± SE, 189 ± 64 pmol/min/mg) [11] , and the results of the present study emphasize that the interpatient variability of the enzyme activity is much larger than that of pharmacokinetic parameters. This work shows a lower mean value of DPD activity in patients with significant toxicity with respect to those who tolerated the treatment well; however, this difference was not significant, and the treatment was well tolerated in some patients who had an apparently low DPD activity in PBMNC.
The statistical analysis of the present data demonstrates that the correlation between 5-FU CL and PBMNC DPD activity was not significant. These results are in agreement with the findings obtained in a study which enrolled 183 patients [11] , but do not confirm the results of a previous study conducted with 57 patients who showed a weak correlation between 5-FU clearance and DPD activity in PBMNC [8] . Because the DPD activity in PBMNC was markedly reduced only in some patients who experienced severe side effects, DPD assay in vitro appears less predictive if compared to 5-FU and 5-FDHU pharmacokinetics to identify patients at risk of severe toxicity by 5-FU [10] . Therefore, the evaluation of PBMNC DPD activity may not be fully predictive of the risk of toxicity. On the contrary, the present study provides evidence that the pharmacokinetic monitoring is a reliable approach for the identification of patients who will develop a severe toxicity and the optimization of 5-FU dosing in each patient on the basis of target AUC Several hypotheses may explain the variable correlation between PBMNC DPD activity and toxicity The PBMNC are characterised by large interpatient variation in DPD content [17] , and changes in leukocyte populations may influence the enzyme activity [18] due to differences in DPD activity among monocytes, lymphocytes and neutrophils These observations may explain the wide inter-and intrapatient variability of DPD, representing additional factors that reduce the reliability of DPD monitoring. Therefore, on the basis of the present results, PBMNC represent a highly variable cellular compartment that may not be suitable to identify all patients with systemic deficiency of 5-FU metabolism, since significant toxicity may be observed in patients with normal DPD activity. Finally, the threshold level of DPD activity, below which a severe toxicity is likely to occur, cannot be established yet, since in a recent study the proposed limit is 100-150 pmol/min/mg protein [13] as compared to less than 60 pmol/min/mg protein in a previous report [14] , with obvious difficulties when comparing earlier data with those obtained in recent studies.
In conclusion, the present results suggest that the pharmacokinetic analysis of 5-FU and 5-FDHU in plasma may contribute to the understanding of the mechanisms of 5-FU metabolism and toxicity, and provide useful information for therapeutic drug monitoring of 5-FU to reduce the risk of developing severe toxicities after drug administration
